What should you know about pt3b melanoma?

The pT3 category is assigned from the measured thickness of the primary melanoma. The b suffix means ulceration was identified in that tumour. Ulceration describes loss of the tumour’s surface covering under microscopic review; it does not automatically mean the cancer has travelled elsewhere. The pT result is combined with lymph-node findings, distant assessment when indicated, and clinical examination to determine the overall stage.

Other report details, including margins and the exact body site, can change the next step. If the wording is difficult to follow, ask the pathologist or treating specialist to connect each finding with a practical decision.

Treatment planning usually includes removal of the melanoma site with an appropriate surgical margin. The laboratory checks the excised tissue, including its edges. Your clinician may discuss sentinel lymph node biopsy because it can provide information about the first lymphatic drainage basin. It is a procedure requiring an individualized discussion of benefits, limitations, and possible complications.

Keep the biopsy and surgical records together, follow wound instructions, and protect the area from sun while it heals. Learn how to inspect the scar, nearby skin, and lymph-node regions, and keep scheduled follow-up visits even when the skin looks settled.

Arrange prompt review for a new or changing mole, repeated bleeding, a firm lump near the treated site, or a new swelling in a nearby lymph-node region. After surgery, report fever, spreading redness, foul or increasing drainage, wound separation, or worsening pain. Go to emergency care for a seizure, sudden weakness, new confusion, difficulty speaking, or a severe new headache. These symptoms can have other causes, but need immediate assessment.

Ask what the measured thickness was, how ulceration was determined, whether the margins are clear, and whether further excision is planned. Discuss sentinel lymph node biopsy, any tests needed to complete staging, warning signs after treatment, and the schedule for skin and lymph-node examinations.